BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 19620487)

  • 1. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.
    Kyriakou C; Canals C; Finke J; Kobbe G; Harousseau JL; Kolb HJ; Novitzky N; Goldstone AH; Sureda A; Schmitz N
    J Clin Oncol; 2009 Aug; 27(24):3951-8. PubMed ID: 19620487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
    J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Duarte RF; Canals C; Onida F; Gabriel IH; Arranz R; Arcese W; Ferrant A; Kobbe G; Narni F; Deliliers GL; Olavarría E; Schmitz N; Sureda A
    J Clin Oncol; 2010 Oct; 28(29):4492-9. PubMed ID: 20697072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
    Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
    Dodero A; Spina F; Narni F; Patriarca F; Cavattoni I; Benedetti F; Ciceri F; Baronciani D; Scimè R; Pogliani E; Rambaldi A; Bonifazi F; Dalto S; Bruno B; Corradini P
    Leukemia; 2012 Mar; 26(3):520-6. PubMed ID: 21904377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.
    Le Gouill S; Milpied N; Buzyn A; De Latour RP; Vernant JP; Mohty M; Moles MP; Bouabdallah K; Bulabois CE; Dupuis J; Rio B; Gratecos N; Yakoub-Agha I; Attal M; Tournilhac O; Decaudin D; Bourhis JH; Blaise D; Volteau C; Michallet M;
    J Clin Oncol; 2008 May; 26(14):2264-71. PubMed ID: 18390969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
    Corradini P; Dodero A; Zallio F; Caracciolo D; Casini M; Bregni M; Narni F; Patriarca F; Boccadoro M; Benedetti F; Rambaldi A; Gianni AM; Tarella C
    J Clin Oncol; 2004 Jun; 22(11):2172-6. PubMed ID: 15169805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
    Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Kyriakou C; Canals C; Cornelissen JJ; Socié G; Willemze R; Ifrah N; Greinix HT; Blaise D; Deconinck E; Ferrant A; Schattenberg A; Harousseau JL; Sureda A; Schmitz N
    J Clin Oncol; 2010 Nov; 28(33):4926-34. PubMed ID: 20956626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
    Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous stem-cell transplantation in patients with HIV-related lymphoma.
    Balsalobre P; Díez-Martín JL; Re A; Michieli M; Ribera JM; Canals C; Rosselet A; Conde E; Varela R; Cwynarski K; Gabriel I; Genet P; Guillerm G; Allione B; Ferrant A; Biron P; Espigado I; Serrano D; Sureda A
    J Clin Oncol; 2009 May; 27(13):2192-8. PubMed ID: 19332732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
    J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
    Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
    Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
    Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
    J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Avivi I; Montoto S; Canals C; Maertens J; Al-Ali H; Mufti GJ; Finke J; Schattenberg A; Fanin R; Cornelissen JJ; Vernant JP; Russell N; Beguin Y; Thomson K; Verdonck LF; Kobbe G; Tilly H; Socié G; Sureda A;
    Br J Haematol; 2009 Dec; 147(5):719-28. PubMed ID: 19793383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.